Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tributyrin in Progressive Supranuclear Palsy (PSP)
NCT07863180Phase 2Recruiting
- Start
- Sep 2026
- Primary completion
- May 2027
- Countries
- 1
01
Overview
Phase 2, randomised trial in progressive supranuclear palsy (PSP) comparing Tributyrin with Placebo (2 arms). Primary endpoints: Tolerability of tributyrin at 90 days and Safety of tributyrin at 90 days. Started Sep 2026; status: recruiting.
02
Drugs
tributyrin
03
Conditions
progressive supranuclear palsy (PSP)
Beyond the preview
Go deeper on NCT07863180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07863180.